You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: studies on the cardiovascular effects of selective COX-2 inhibitors show mixed results

https://doi.org/10.1136/ebm.7.2.49

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    (2001) JAMA 286, 954. Mukherjee D, Nissen SE, Topol EJ.. Risk of cardiovascular events associated with selective COX-2 inhibitors.. Aug 22/29;. :. –9.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 QUESTION: In patients with arthritis, do rofecoxib or celecoxib increase the risk for cardiovascular events?

    Data sources

    Studies were identified by searching Medline (1998 to February 2001) and the internet. The Adverse Events Reporting System was searched for US events on October 12, 2000.

    Study selection

    English language studies were selected if they were randomised, double blind, controlled trials reporting the cardiovascular effects of celecoxib or rofecoxib.

    Data extraction

    Data were extracted on study methods, patient characteristics, drug regimens, aspirin use, and cardiovascular events.

    Main results

    4 studies met the selection criteria. The Vioxx Gastrointestinal Outcomes Research study compared rofecoxib 50 mg/day, with naproxen 1000 mg/day, in 8076 patients with rheumatoid arthritis. Aspirin use was not permitted. Patients in the rofecoxib group had an increased risk for …

    View Full Text

    Footnotes

    • ↵* Numbers calculated from data in article

    • Source of funding: not stated.

    • For correspondence: Dr E J Topol, Cleveland Clinic Foundation, Cleveland, OH, USA. topole{at}ccf.org.